Endocan attenuates LPS-induced alveolar type II cells injury through PI3K/Akt/mTOR pathway

  • Yulu Zhao The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China https://orcid.org/0009-0004-1476-8712
  • Zekai Wang Department of Pathophysiology, School of Basic Medical Sciences, The Research Institute of Microbiota and Host Inflammation-Related Diseases, Wenzhou Medical University, Wenzhou, China https://orcid.org/0009-0000-3240-186X
  • Ming Luo The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China
  • Jinling Yang The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China; and Department of Anesthesiology, Critical Care and Pain Medicine, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China https://orcid.org/0009-0003-4973-0522
  • Zhixiang Geng The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China; and Department of Anesthesiology, Critical Care and Pain Medicine, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China https://orcid.org/0009-0004-4107-6914
  • Shining Ou Department of Pathophysiology, School of Basic Medical Sciences, The Research Institute of Microbiota and Host Inflammation-Related Diseases, Wenzhou Medical University, Wenzhou, China https://orcid.org/0009-0001-3732-7395
  • Zhenxuan Huang Department of Pathophysiology, School of Basic Medical Sciences, The Research Institute of Microbiota and Host Inflammation-Related Diseases, Wenzhou Medical University, Wenzhou, China https://orcid.org/0009-0008-2740-7042
  • Ruiqi Sun Department of Pathophysiology, School of Basic Medical Sciences, The Research Institute of Microbiota and Host Inflammation-Related Diseases, Wenzhou Medical University, Wenzhou, China https://orcid.org/0009-0008-8997-7817
  • Fangyan Wang
  • Xiang Luo Department of Chemical and Environmental Engineering, The University of Nottingham Ningbo China, Ningbo, PR China https://orcid.org/0000-0002-6040-5419
  • Keke Jin Department of Pathophysiology, School of Basic Medical Sciences, The Research Institute of Microbiota and Host Inflammation-Related Diseases, Wenzhou Medical University, Wenzhou, China https://orcid.org/0000-0002-6020-318X
  • Xiaolong Zhang The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China; and Department of Anesthesiology, Critical Care and Pain Medicine, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China https://orcid.org/0000-0002-1652-1586
DOI: https://doi.org/10.48101/ujms.v131.13337
Keywords: Endocan, mTOR, ALI, lipopolysaccharide, alveolar type II cell

Abstract

Background: Alveolar type II (AT2) cell injury plays an important role in the pathogenesis of acute lung injury (ALI), but the corresponding treatment options are limited in clinical practice. Endocan has been proved to exert a protective effect in ALI, however, the underlying mechanism remains unclear. The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) signaling pathway was found to exhibit beneficial effects in lipopolysaccharide-induced ALI. This study aimed to investigate protective effects of endocan on AT2 cells and the signal pathway in LPS-induced ALI.

Methods: Pulmonary function testing and hematoxylin–eosin staining were employed to evaluate the effects of endocan on the LPS-induced ALI in mice. Transmission electron microscopy (TEM) analysis, immunofluorescence and Western blot were used to assess the AT2 protection of endocan. Mouse lung epithelial cell line 12 (MLE-12) cells were facilitated to observe the activation of PI3K/AKT/mTOR pathway.

Results: Endocan administration effectively ameliorated respiratory parameters in LPS-challenged ALI mice. TEM revealed that endocan treatment preserved AT2 cell integrity and maintained lamellar body ultrastructure compared to the mice injected LPS only. Western blot analysis showed a higher surfactant protein C expression in endocan-treated mice than that of model group. Moreover, the phosph-PI3K, -AKT, -mTOR levels detected by Western blot were significantly observed upregulated after endocan treatment. However, rapamycin, an mTOR inhibitor, abolished the protective effects of endocan against ALI, indicating this pathway may be critical for its action on AT2 cells. In LPS-treated MLE-12 cells, the Western blot analysis further confirmed that rapamycin suppressed endocan-induced activation of the PI3K/AKT/mTOR pathway, thereby attenuating the protective effects of endocan on MLE-12 cells.

Conclusion: Endocan protects AT2 cells against ALI through activating PI3K/AKT/mTOR pathway, suggesting its therapeutic potential for AT2 in patients with ALI.

Downloads

Download data is not yet available.

References


1.
Xia L, Zhang C, Lv N, Liang Z, Ma T, Cheng H, et al. AdMSC-derived exosomes alleviate acute lung injury via transferring mitochondrial component to improve homeostasis of alveolar macrophages. Theranostics. 2022;12(6):2928–47. doi: https://doi.org/10.7150/thno.69533

2.
Zhang J, Zhang M, Zhu QM, Xu XR, Feng YL, Lin S, et al. Allosteric regulation of Keap1 by 8β-hydroxy-α-cyclocostunolide for the treatment of acute lung injury. Acta Pharm Sin B. 2024;14(9):4174–8. doi: https://doi.org/10.1016/j.apsb.2024.06.025

3.
Mokrá D. Acute lung injury – from pathophysiology to treatment. Physiol Res. 2020;69:S353–S66. doi: https://doi.org/10.33549/physiolres.934602

4.
Paris AJ, Hayer KE, Oved JH, Avgousti DC, Toulmin SA, Zepp JA, et al. STAT3-BDNF-TrkB signalling promotes alveolar epithelial regeneration after lung injury. Nat Cell Biol. 2020;22(10):1197–210. doi: https://doi.org/10.1038/s41556-020-0569-x

5.
Sha HX, Liu YB, Qiu YL, Zhong WJ, Yang NS, Zhang CY, et al. Neutrophil extracellular traps trigger alveolar epithelial cell necroptosis through the cGAS-STING pathway during acute lung injury in mice. Int J Biol Sci. 2024;20(12):4713–30. doi: https://doi.org/10.7150/ijbs.99456

6.
Chen X, Zhang C, Wei T, Chen J, Pan T, Li M, et al. α7nAChR activation in AT2 cells promotes alveolar regeneration through WNT7B signaling in acute lung injury. JCI Insight. 2023;8(15):e162547. doi: https://doi.org/10.1172/jci.insight.162547

7.
Scherpereel A, Gentina T, Grigoriu B, Sénéchal S, Janin A, Tsicopoulos A, et al. Overexpression of endocan induces tumor formation. Cancer Res. 2003;63(18):6084–9.

8.
Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271(34):20458–64. doi: https://doi.org/10.1074/jbc.271.34.20458

9.
Hureau M, Portier L, Prin M, De Nadai P, Balsamelli J, Tsicopoulos A, et al. Evaluation of endocan as a treatment for acute inflammatory respiratory failure. Cells. 2023;12(2):257. doi: https://doi.org/10.3390/cells12020257

10.
Zhang SM, Zuo L, Zhou Q, Gui SY, Shi R, Wu Q, et al. Expression and distribution of endocan in human tissues. Biotech Histochem. 2012;87(3):172–8. doi: https://doi.org/10.3109/10520295.2011.577754

11.
Zheng X, Soroush F, Long J, Hall ET, Adishesha PK, Bhattacharya S, et al. Murine glomerular transcriptome links endothelial cell-specific molecule-1 deficiency with susceptibility to diabetic nephropathy. PLoS One. 2017;12(9):e0185250. doi: https://doi.org/10.1371/journal.pone.0185250

12.
De Freitas Caires N, Gaudet A, Portier L, Tsicopoulos A, Mathieu D, Lassalle P, et al. Endocan, sepsis, pneumonia, and acute respiratory distress syndrome. Crit Care. 2018;22(1):280. doi: https://doi.org/10.1186/s13054-018-2222-7

13.
Zhang X, Zhuang R, Wu H, Chen J, Wang F, Li G, et al. A novel role of endocan in alleviating LPS-induced acute lung injury. Life Sci. 2018;202:89–97. doi: https://doi.org/10.1016/j.lfs.2018.04.005

14.
Orbegozo D, Rahmania L, Irazabal M, Mendoza M, Annoni F, De Backer D, et al. Endocan as an early biomarker of severity in patients with acute respiratory distress syndrome. Ann Intensive Care. 2017;7(1):93. doi: https://doi.org/10.1186/s13613-017-0311-4

15.
Ying J, Zhou D, Gu T, Huang J. Endocan, a risk factor for developing acute respiratory distress syndrome among severe pneumonia patients. Can Respir J. 2019;2019:2476845. doi: https://doi.org/10.1155/2019/2476845

16.
Yu L, Wei J, Liu P. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol. 2022;85:69–94. doi: https://doi.org/10.1016/j.semcancer.2021.06.019

17.
Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol. 2005;23(10):2411–22. doi: https://doi.org/10.1200/JCO.2005.03.089

18.
Wang C, Zou K, Diao Y, Zhou C, Zhou J, Yang Y, et al. Liensinine alleviates LPS-induced acute lung injury by blocking autophagic flux via PI3K/AKT/mTOR signaling pathway. Biomed Pharmacother. 2023;168:115813. doi: https://doi.org/10.1016/j.biopha.2023.115813

19.
Feng T, Zhou L, Gai S, Zhai Y, Gou N, Wang X, et al. Acacia catechu (L.f.) Willd and Scutellaria baicalensis Georgi extracts suppress LPS-induced pro-inflammatory responses through NF-кB, MAPK, and PI3K-Akt signaling pathways in alveolar epithelial type II cells. Phytother Res. 2019;33(12):3251–60. doi: https://doi.org/10.1002/ptr.6499

20.
Gaudet A, Portier L, Prin M, Copin MC, Tsicopoulos A, Mathieu D, et al. Endocan regulates acute lung inflammation through control of leukocyte diapedesis. J Appl Physiol (1985). 2019;127(3):668–78. doi: https://doi.org/10.1152/japplphysiol.00337.2019

21.
Li N, Liu B, Xiong R, Li G, Wang B, Geng Q. HDAC3 deficiency protects against acute lung injury by maintaining epithelial barrier integrity through preserving mitochondrial quality control. Redox Biol. 2023;63:102746. doi: https://doi.org/10.1016/j.redox.2023.102746

22.
Ortiz ME, Thurman A, Pezzulo AA, Leidinger MR, Klesney-Tait JA, Karp PH, et al. Heterogeneous expression of the SARS-coronavirus-2 receptor ACE2 in the human respiratory tract. EBioMedicine. 2020;60:102976. doi: https://doi.org/10.1016/j.ebiom.2020.102976

23.
Laloglu E, Alay H. Endocan as a potential marker in diagnosis and predicting disease severity in COVID-19 patients: a promising biomarker for patients with false-negative RT-PCR. Ups J Med Sci. 2022;12:8211.

24.
Brown EJ, Albers MW, Shin TB, Ichikawa Ichikawa K, Keith CT, Lane WS, K, Keith CT, Lane WS, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369(6483):756–8. doi: https://doi.org/10.48101/ujms.v127.8211

25.
Ding Z, Zhong R, Xia T, Yang Y, Xing N, Wang W, et al. Advances in research into the mechanisms of Chinese Materia Medica against acute lung injury. Biomed Pharmacother. 2020;122:109706. doi: https://doi.org/10.1016/j.biopha.2019.109706

26.
Pan KF, Yang YC, Lee WJ, Hua KT, Chien MH. Proteoglycan endocan: a multifaceted therapeutic target in cancer. Biochim Biophys Acta Rev Cancer. 2022;1877(1):188672. doi: https://doi.org/10.1016/j.bbcan.2021.188672

27.
Ioakeimidou A, Pagalou E, Kontogiorgi M, Antoniadou E, Kaziani K, Psaroulis K, et al. Increase of circulating endocan over sepsis follow-up is associated with progression into organ dysfunction. Eur J Clin Microbiol Infect Dis. 2017;36(10):1749–56. doi: https://doi.org/10.1007/s10096-017-2988-6

28.
Mikkelsen ME, Shah CV, Scherpereel A, Lanken PN, Lassalle P, Bellamy SL, et al. Lower serum endocan levels are associated with the development of acute lung injury after major trauma. J Crit Care. 2012;27(5):522.e11–17. doi: https://doi.org/10.1016/j.jcrc.2011.07.077

29.
Gaudet A, Portier L, Mathieu D, Hureau M, Tsicopoulos A, Lassalle P, et al. Cleaved endocan acts as a biologic competitor of endocan in the control of ICAM-1-dependent leukocyte diapedesis. J Leukoc Biol. 2020;107(5):833–41. doi: https://doi.org/10.1002/JLB.3AB0320-612RR

30.
Li Y, Huang J, Foley NM, Xu Y, Li YP, Pan J, et al. B7H3 ameliorates LPS-induced acute lung injury via attenuation of neutrophil migration and infiltration. Sci Rep. 2016;6:31284. doi: https://doi.org/10.1038/srep31284

31.
Haczku A. Protective role of the lung collectins surfactant protein A and surfactant protein D in airway inflammation. J Allergy Clin Immunol. 2008;122(5):861–79; quiz 80–1. doi: https://doi.org/10.1016/j.jaci.2008.10.014

32.
Whitsett JA. Review: the intersection of surfactant homeostasis and innate host defense of the lung: lessons from newborn infants. Innate Immun. 2010;16(3):138–42. doi: https://doi.org/10.1177/1753425910366879

33.
Tang X, Snowball JM, Xu Y, Na CL, Weaver TE, Clair G, et al. EMC3 coordinates surfactant protein and lipid homeostasis required for respiration. J Clin Invest. 2017;127(12):4314–25. doi: https://doi.org/10.1172/JCI94152

34.
Keller A, Eistetter HR, Voss T, Schäfer KP. The pulmonary surfactant protein C (SP-C) precursor is a type II transmembrane protein. Biochem J. 1991;277:493–9. doi: https://doi.org/10.1042/bj2770493

35.
Mossmann D, Park S, Hall MN. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer. 2018;18(12):744–57. doi: https://doi.org/10.1038/s41568-018-0074-8

36.
Zhao P, Wu Z, Chen H. MicroRNA-107 alleviates ferroptosis-mediated acute kidney injury by regulating the PI3K/Akt/mTOR pathway. BMC Nephrol. 2025;27:61. doi: https://doi.org/10.1186/s12882-024-03913-3

37.
Li Y, Liu Y, Shi Z, He M. SIRT3 inhibits autophagy-dependent ferroptosis of HUVECs in the progression of pregnancy-induced hypertension by activating the PI3K/Akt/mTOR axis. Front Mol Neurosci. 2025;18:1620184. doi: https://doi.org/10.3389/fnmol.2025.1620184

38.
Wu YF, Li ZY, Dong LL, Li WJ, Wu YP, Wang J, et al. Inactivation of MTOR promotes autophagy-mediated epithelial injury in particulate matter-induced airway inflammation. Autophagy. 2020;16(3):435–50. doi: https://doi.org/10.1080/15548627.2019.1628536

39.
Xie T, Xu Q, Wan H, Xing S, Shang C, Gao Y, et al. Lipopolysaccharide promotes lung fibroblast proliferation through autophagy inhibition via activation of the PI3K-Akt-mTOR pathway. Lab Invest. 2019;99(5): 625–33. doi: https://doi.org/10.1038/s41374-018-0160-2

40.
Hu X, Xu Q, Wan H, Hu Y, Xing S, Yang H, et al. PI3K-Akt-mTOR/PFKFB3 pathway mediated lung fibroblast aerobic glycolysis and collagen synthesis in lipopolysaccharide-induced pulmonary fibrosis. Lab Invest. 2020;100(6):801–11. doi: https://doi.org/10.1038/s41374-020-0404-9

41.
Qiao X, Wang H, He Y, Song D, Altawil A, Wang Q, et al. Grape seed proanthocyanidin ameliorates LPS-induced acute lung injury by modulating M2a macrophage polarization via the TREM2/PI3K/Akt pathway. Inflammation. 2023;46(6):2147–64. doi: https://doi.org/10.1007/s10753-023-01868-5

42.
Domscheit H, Hegeman MA, Carvalho N, Spieth PM. Molecular dynamics of lipopolysaccharide-induced lung injury in rodents. Front Physiol. 2020;11:36. doi: https://doi.org/10.3389/fphys.2020.00036

43.
Lee CH, Inoki K, Guan KL. mTOR pathway as a target in tissue hypertrophy. Annu Rev Pharmacol Toxicol. 2007;47:443–67. doi: https://doi.org/10.1146/annurev.pharmtox.47.120505.105359

44.
Li D, Zhang X, Song Z, Zhao S, Huang Y, Qian W, et al. Advances in common in vitro cellular models of pulmonary fibrosis. Immunol Cell Biol. 2024;102(7):557–69. doi: https://doi.org/10.1111/imcb.12756
Published
2026-03-04
How to Cite
Zhao , Y., Wang , Z., Luo , M., Yang , J., Geng , Z., Ou , S., Huang , Z., Sun , R., Wang , F., Luo , X., Jin , K., & Zhang , X. (2026). Endocan attenuates LPS-induced alveolar type II cells injury through PI3K/Akt/mTOR pathway. Upsala Journal of Medical Sciences, 131, e13337. https://doi.org/10.48101/ujms.v131.13337
Issue
Vol. 131 (2026): Upsala J Med Sci - Issue in Progress
Section
Original Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain copyright of their work, with first publication rights granted to Upsala Medical Society. Read the full Copyright- and Licensing Statement.

Crossref
Scopus
Google Scholar
Europe PMC